Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813359 | 0.95 | FLT3 (0.36) | FLT3MKNK1MKNK2CNR1CNR2 | |
| SCHEMBL27217958 | 0.90 | VCP (0.31) | — | |
| SCHEMBL27088011 | 0.86 | RET (0.33) | FLT3MKNK2 | |
| SCHEMBL30813722 | 0.85 | PDPK1 (0.32) | FLT3MKNK2 | |
| SCHEMBL27217811 | 0.83 | — | — | |
| SCHEMBL30813659 | 0.82 | PDPK1 (0.33) | FLT3MKNK2 | |
| SCHEMBL27218030 | 0.82 | PDPK1 (0.33) | FLT3MKNK2 | |
| SCHEMBL29998193 | 0.80 | RET (0.34) | FLT3MKNK2 | |
| SCHEMBL27217840 | 0.78 | FLT3 (0.37) | FLT3 | |
| SCHEMBL30813590 | 0.78 | PDPK1 (0.32) | FLT3MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | FLT3 3178/4885MKNK1 196/4885MKNK2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.